Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A

Phase 1 to evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A. Which is designed as ramdomized, oral, single dose, two-way crossover.

Inclusion Criteria:

• Over 19 ages healthy men
• Over 50.0kg, 18.0kg/m2 ≤ BMI ≤ 30.0kg/m2
• Men who don't have congenital disease and other cronic disease need to be cared. etc.

Exclusion Criteria:

• Men who have congenital liver disease (AST, ALT, CK ≥ 2X ULN)
• Men who have drunken or eatten something including caffeine within 24 hours before. etc.